The Clinical Research Unit (CRU) is critical to the conduct of clinical research at the Abramson Cancer Center (ACC). This core is a centralized administrative unit that coordinates protocol management, budget and financial analysis, regulatory affairs expertise, research nursing support, and data management for therapeutic clinical trials conducted by ACC investigators. The CRU supports peer-reviewed funded clinical research projects, invesfigator-initiated clinical trials, cooperative group trials, and industry-sponsored trials. All trials supported by the CRU are approved by the ACC Clinical Trials Scientific Review and Monitoring Committee and are subject to ACC Data and Safety Monitoring Committee internal audits. By providing the necessary infrastructure for the transfer of preclinical discoveries into the clinic, this core is central to the ACC mission to support translational research and high impact clinical trials. The availability of a senior scientific leader, who is an expert in clinical trials management, as well as highly skilled research personnel, allows ACC clinical invesfigators to develop and conduct a comprehensive range of clinical trials for all types of cancer that involve both novel agents and innovative treatment approaches. In response to the 2004 CCSG critique ofthe CRU, the ACC has implemented Velos eResearch, a clinical trials management system. This information system will improve efficiency of CRU operations and ensure data standardization and regulatory compliance. Additional changes in the clinical research infrastructure have enhanced the function of this core. These include the establishment of disease-specific research groups charged with the responsibility of managing their portfolio of clinical trials, based upon scienfific goals and available resources; the establishment ofthe Strategic Planning and Resource Committee, a centralized group that reviews a proposed protocol to be certain that adequate resources are available to support the trial and that the budget is appropriate. These additional reviews help assure that the resources ofthe CRU are focused on the highest priority clinical trials conducted by ACC members. From 1/2009 to 12/2009 49 new therapeutic clinical trials have been activated by the CRU. CCSG support represents 20% ofthe core's proposed budget with the remaining funding coming from other grants/contracts and institutional support.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016520-38
Application #
8593284
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$458,731
Indirect Cost
$86,401
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Hinderer, Christian; Katz, Nathan; Buza, Elizabeth L et al. (2018) Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum Gene Ther 29:285-298
Li, Jinyang; Byrne, Katelyn T; Yan, Fangxue et al. (2018) Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity 49:178-193.e7
Raghunathan, Nirupa Jaya; Korenstein, Deborah; Li, Qing S et al. (2018) Determinants of mobile technology use and smartphone application interest in cancer patients. Cancer Med 7:5812-5819
Hordeaux, Juliette; Wang, Qiang; Katz, Nathan et al. (2018) The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice. Mol Ther 26:664-668
Echevarría-Vargas, Ileabett M; Reyes-Uribe, Patricia I; Guterres, Adam N et al. (2018) Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. EMBO Mol Med 10:
Torre, Eduardo; Dueck, Hannah; Shaffer, Sydney et al. (2018) Rare Cell Detection by Single-Cell RNA Sequencing as Guided by Single-Molecule RNA FISH. Cell Syst 6:171-179.e5
Vonderheide, Robert H (2018) The Immune Revolution: A Case for Priming, Not Checkpoint. Cancer Cell 33:563-569
Romero, Sally A D; Jones, Lee; Bauml, Joshua M et al. (2018) The association between fatigue and pain symptoms and decreased physical activity after cancer. Support Care Cancer 26:3423-3430
Safo, Sandra E; Li, Shuzhao; Long, Qi (2018) Integrative analysis of transcriptomic and metabolomic data via sparse canonical correlation analysis with incorporation of biological information. Biometrics 74:300-312
Kall, Stefanie L; Delikatny, Edward J; Lavie, Arnon (2018) Identification of a Unique Inhibitor-Binding Site on Choline Kinase ?. Biochemistry 57:1316-1325

Showing the most recent 10 out of 1047 publications